 See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License
Review Article
3726
Cancer   November 1, 2019FUNDING SUPPORT
This work was supported by National Cancer Institute (grants 
R01-CA72038, R01-CA207270), the Cancer Prevention and Research 
Institute of Texas Multi-Investigator Research Award (RP120732), the 
Breast Cancer Research Foundation (grant 18-055), and NIH NCI 
(grant 5P30 CA125123).
CONFLICT OF INTEREST DISCLOSURES
The authors made no disclosures.
REFERENCES
 1. American Cancer Society. Breast Cancer Facts & Figures 2017-2018. 
Atlanta, GA: American Cancer Society; 2017.
 2. Barone I, Iacopetta D, Covington KR, et al. Phosphorylation of the mutant K303R estrogen receptor alpha at serine 305 affects aro -
matase inhibitor sensitivity. Oncogene . 2010;29:2404-2414.
 3. Fuqua SA, Gu G, Rechoum Y. Estrogen receptor (ER) alpha muta -
tions in breast cancer: hidden in plain sight. Breast Cancer Res Treat . 
2014;144:11-19.
 4. Razavi P, Chang MT, Xu G, et al. The genomic landscape of endo -
crine-resistant advanced breast cancers. Cancer Cell . 2018;34:427-438.
 5. Turner NC, Ro J, Andre F, et al. Palbociclib in hormone-recep -
tor-positive advanced breast cancer. N Engl J Med . 2015;373:209-219.
 6. Finn RS, Martin M, Rugo HS, et al. Palbociclib and letrozole in ad -
vanced breast cancer. N Engl J Med . 2016;375:1925-1936.
 7. Hortobagyi GN, Stemmer SM, Burris HA, et al. Ribociclib as first-
line therapy for HR-positive, advanced breast cancer. N Engl J Med . 
2016;375:1738-1748.
 8. Goetz MP, Toi M, Campone M, et al. MONARCH 3: abemac -
iclib as initial therapy for advanced breast cancer. J Clin Oncol . 
2017;35:3638-3646.
 9. Fribbens C, Oâ€™Leary B, Kilburn L, et al. Plasma ESR1  mutations and 
the treatment of estrogen receptor-positive advanced breast cancer.  
J Clin Oncol . 2016;34:2961-2968.
 10. Chandarlapaty S, Chen D, He W, et al. Prevalence of ESR1  muta -
tions in cell-free DNA and outcomes in metastatic breast cancer: a 
secondary analysis of the BOLERO-2 clinical trial. JAMA Oncol . 
2016;2:1310-1315.
 11. Fuqua SA, Wiltschke C, Zhang QX, et al. A hypersensitive estrogen receptor-alpha mutation in premalignant breast lesions. Cancer Res . 
2000;60:4026-4029.
 12. Toy W, Weir H, Razavi P, et al. Activating ESR1  mutations dif -
ferentially affect the efficacy of ER antagonists. Cancer Discov . 
2017;7:277-287.
 13. Zhang QX, Borg A, Wolf DM, Oesterreich S, Fuqua SA. An estrogen 
receptor mutant with strong hormone-independent activity from a 
metastatic breast cancer. Cancer Res . 1997;57:1244-1249.
 14. Gelsomino L, Gu G, Rechoum Y, et al. ESR1  mutations affect an -
ti-proliferative responses to tamoxifen through enhanced cross-talk 
with IGF signaling. Breast Cancer Res Treat . 2016;157:253-265.
 15. Toy W, Shen Y, Won H, et al. ESR1  ligand-binding domain mutations 
in hormone-resistant breast cancer. Nat Genet . 2013;45:1439-1445.
 16. Robinson DR, Wu YM, Vats P, et al. Activating ESR1  muta -
tions in hormone-resistant metastatic breast cancer. Nat Genet . 
2013;45:1446-1451.
 17. Pavlin M, Spinello A, Pennati M, et al. A computational assay of es -
trogen receptor alpha antagonists reveals the key common structural 
traits of drugs effectively fighting refractory breast cancers. Sci Rep . 
2018;8:649.
 18. Gates LA, Gu G, Chen Y, et al. Proteomic profiling identifies key 
coactivators utilized by mutant ERalpha proteins as potential new therapeutic targets. Oncogene . 2018;37:4581-4598.
 19. Merenbakh-Lamin K, Ben-Baruch N, Yeheskel A, et al. D538G mu -
tation in estrogen receptor-alpha: a novel mechanism for acquired en -
docrine resistance in breast cancer. Cancer Res . 2013;73:6856-6864.
 20. Jeselsohn R, Bergholz JS, Pun M, et al. Allele-specific chromatin re -
cruitment and therapeutic vulnerabilities of ESR1  activating muta -
tions. Cancer Cell . 2018;33:173-186. 21. Harrod A, Fulton J, Nguyen VTM, et al. Genomic modelling of the 
ESR1  Y537S mutation for evaluating function and new therapeutic ap -
proaches for metastatic breast cancer. Oncogene . 2017;36:2286-2296.
 22. Bahreini A, Li Z, Wang P, et al. Mutation site and context dependent 
effects of ESR1  mutation in genome-edited breast cancer cell models. 
Breast Cancer Res . 2017;19:60.
 23. Martin LA, Ribas R, Simigdala N, et al. Discovery of naturally oc -
curring ESR1  mutations in breast cancer cell lines modelling endo -
crine resistance. Nat Commun . 2017;8:1865.
 24. Li Z, Levine KM, Bahreini A, et al. Upregulation of IRS1 enhances 
IGF1 response in Y537S and D538G ESR1  mutant breast cancer 
cells. Endocrinology . 2018;159:285-296.
 25. Gu G, Rechoum Y, Gelsomino L, et al. The Y537S ESR1  mutation 
is a dominant driver of distant ER-positive breast cancer metastasis.